Outpatient Utilization of COVID-19 Treatments Under Emergency Use Authorization (EUA): A Simplified Descriptive Analysis for Paxlovid and other EUA Drugs Descriptive
bamlanivimab,
bamlanivimab etesevimab,
bebtelovimab,
casirivimab imdevimab,
molnupiravir,
nirmatrelvir and ritonavir,
remdesivir
View More Medical Product (7)
01/16/2025
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: An Updated Descriptive Analysis Descriptive
12/31/2024
Characterization of Dispensing Patterns of Baricitinib, Ritlecitinib, and Upadacitinib in Patients with Alopecia, Crohn's Disease, Ulcerative Colitis, and Inflammatory Bowel Disease: A Descriptive Analysis Descriptive
12/20/2024
Utilization of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis TriNetX Analysis
12/11/2024
Demographic Characteristics of Incident Users of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis TriNetX Analysis
12/11/2024
Clinical Characteristics of Incident Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in TriNetX: A Descriptive Analysis TriNetX Analysis
12/11/2024
Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Descriptive Analysis Descriptive
12/10/2024
Risk of Severe Hyperglycemia Following Systemic Corticosteroids and Azithromycin Use in COVID-19 Patients with Type 2 Diabetes: A Sequential Surveillance Analysis Prospective Sequential Inferential
12/04/2024
Corticosteroid Utilization Patterns in Hospitalized Patients With and Without a COVID-19 Diagnosis in TriNetX: A Descriptive Analysis TriNetX Analysis
12/03/2024
Occurrence of Absolute Neutrophil Count (ANC) Monitoring and Neutropenia Following Clozapine Use in Patients from Sentinel Data Partners that Curate ANC Laboratory Results: A Descriptive Analysis Descriptive
12/03/2024
Occurrence of Absolute Neutrophil Count (ANC) Monitoring, ANC Laboratory Results, and Neutropenia Following Clozapine Use: A Descriptive Analysis Descriptive
12/03/2024
Characterization of Users of Inclisiran in TriNetX: A Descriptive Analysis TriNetX Analysis
11/27/2024
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Third Descriptive Analysis Descriptive
11/19/2024
Clozapine Use: First Descriptive Analysis Descriptive
11/19/2024
Clozapine Use: Second Descriptive Analysis Descriptive
11/19/2024
Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: First Descriptive Analysis Descriptive
11/19/2024
Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: Second Descriptive Analysis Descriptive
11/19/2024
Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: Third Descriptive Analysis Descriptive
11/19/2024
Rates of Nervous System Disorders Following Bortezomib Use in Patients: A Descriptive Analysis Descriptive
11/18/2024
Cancer Rates Among Individuals with Loop Diuretics Exposure: A Descriptive Analysis Descriptive
11/14/2024
Utilization of Valsartan: A Descriptive Analysis Descriptive
11/12/2024
Utilization of Risankizumab and Comparator Products: A Descriptive Analysis Descriptive
11/07/2024
Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis Descriptive
11/06/2024
Characterization of Users of Atogepant in TriNetX: A Descriptive Analysis TriNetX Analysis
11/06/2024
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Descriptive Analysis Descriptive
11/06/2024
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: An Updated Descriptive Analysis Descriptive
11/06/2024
Trends in Healthcare Encounters with Evidence of Disorders Related to the Use, Abuse, or Dependence of Cannabis, Cocaine, or Alcohol: A Descriptive Analysis Descriptive
11/06/2024
Trends in Healthcare Encounters with Evidence of Poisoning by Cannabis, Cocaine, Alcohol, Heroin, or Benzodiazepines: A Descriptive Analysis Descriptive
11/06/2024
Characteristics of Patients with Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis, Cocaine, Alcohol, Heroin, or Benzodiazepines: A Descriptive Analysis Descriptive
11/06/2024
Characteristics of Patients with Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis: A Descriptive Analysis Descriptive
11/06/2024
Trends in Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis, Stratified by the Legality Status of Cannabis by State and Territory: A Descriptive Analysis Descriptive
11/06/2024
Outcome Monitoring Following Guselkumab Use: A Signal Identification and Self-Controlled Risk Interval Analysis Signal Identification
11/01/2024
Utilization of Methotrexate: A Descriptive Analysis Descriptive
10/28/2024
Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Second Descriptive Analysis Descriptive
10/25/2024
Counts and Characteristics of Local Anesthetic Toxicity Summary Table
10/23/2024
Utilization of Products with Labeling Changes Related to Pregnancy Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Descriptive
10/02/2024
Outcome Monitoring Following Risankizumab Use: A Signal Identification Analysis Signal Identification
10/01/2024
Outcome Monitoring Following Risankizumab Use: A Supplemental Signal Identification Analysis Signal Identification
10/01/2024
Outcome Monitoring Following Guselkumab Use: A Signal Identification Analysis Signal Identification
09/17/2024
Counts and Characteristics of Individuals with Prurigo Nodularis and Other Dermatologic Conditions: A Descriptive Analysis Descriptive
09/03/2024
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Updated Interrupted Time Series Analysis Retrospective Inferential
08/26/2024
Trends in Healthcare Utilization During the COVID-19 Pandemic: A Propensity Score Matched and Stratified Analysis in the Sentinel Distributed Database Retrospective Inferential
08/21/2024
Trends in Healthcare Utilization During the COVID-19 Pandemic: A Propensity Score Matched and Stratified Analysis in Merative™ MarketScan® Research Databases Retrospective Inferential
08/21/2024
Characteristics and Drug Utilization in Dabigatran, Rivaroxaban, and Apixaban Initiators Aged 64 or Younger: A Descriptive Analysis Descriptive
08/21/2024
Thromboembolic Stroke, Intracranial Hemorrhage, Gastrointestinal Bleeding, and Major Extracranial Bleeding Following Apixaban, Dabigatran, and Rivaroxaban Use in Patients Aged 64 Years and Younger with Atrial Fibrillation: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential
gastrointestinal bleeding
, intracranial hemorrhage
, major extracranial hemorrhage
, thromboembolic stroke
View More Outcomes (4)
08/21/2024
Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: An Updated Descriptive Analysis Descriptive
08/09/2024
Characteristics and Drug Utilization in Pregnant Patients With COVID-19: A Propensity Score Matched Analysis Retrospective Inferential
08/08/2024
Risk of Adverse Maternal Health Outcomes Among Pregnant Patients With and Without COVID-19: A Propensity Score Matched Analysis Retrospective Inferential
08/07/2024
Risk of Adverse Neonatal Health Outcomes Among Pregnant Patients With and Without COVID-19: A Propensity Score Matched Analysis Retrospective Inferential
08/02/2024
Utilization of Dupilumab: A Descriptive Analysis Descriptive
07/31/2024
Duration of Follow Up for New Molecular Entities Approved in 2017: Third Descriptive Analysis Descriptive
07/30/2024
Duration of Follow Up for New Molecular Entities Approved in 2018: Second Descriptive Analysis Descriptive
07/30/2024
Duration of Follow Up for New Molecular Entities Approved in 2019: Second Descriptive Analysis Descriptive
07/30/2024
Duration of Follow Up for New Molecular Entities Approved in 2020: First Descriptive Analysis Descriptive
07/30/2024
Duration of Follow Up for New Molecular Entities Approved in 2021: First Descriptive Analysis Descriptive
07/30/2024
Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Descriptive Analysis Descriptive
07/26/2024
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis Descriptive
07/22/2024
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential
07/22/2024
Utilization of Methotrexate: A Descriptive Analysis in TriNetX TriNetX Analysis
07/17/2024
Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis Descriptive
07/17/2024
Counts and Characteristics of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor or Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Users with Type 2 Diabetes: A Descriptive Analysis Descriptive
07/11/2024
Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential
06/24/2024
Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: An Updated Descriptive Analysis Descriptive
06/10/2024
Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: An Updated Descriptive Analysis TriNetX Analysis
05/30/2024
Utilization of Beta Blockers in the Pediatric Population: A Follow Up Updated Descriptive Analysis Descriptive
05/20/2024
Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis Descriptive
05/17/2024
Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis in TriNetX TriNetX Analysis
05/17/2024
Duration of Follow Up for New Molecular Entities Approved in 2007: A Descriptive Analysis Summary Table
05/14/2024
Interstitial Lung Disease (ILD) in Patients with Inflammatory Bowel Disease (IBD) and Following Vedolizumab or Natalizumab Initiation: A Descriptive Analysis Descriptive
05/09/2024
Interstitial Lung Disease (ILD) Rates in Patients with Inflammatory Bowel Disease (IBD) and Following IBD Advanced Therapy: A Descriptive Analysis Descriptive
adalimumab,
certolizumab,
etrasimod,
golimumab,
infliximab,
mirikizumab,
ozanimod,
risankizumab,
tofacitinib,
upadacitinib,
ustekinumab
View More Medical Product (11)
05/09/2024
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis Retrospective Inferential
04/23/2024
Validation of Hospitalized COVID-19 Diagnosis Detected from Claims-Based Algorithms: A Descriptive Analysis Site-Specific Query
04/22/2024
Utilization of Products Over Time for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Descriptive
04/19/2024
Utilization of Loop Diuretics: A Descriptive Analysis Descriptive
04/12/2024
Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis TriNetX Analysis
04/10/2024
Count and Duration of Follow-up of New-Onset Cancer: A Descriptive Analysis Descriptive
03/22/2024
Intentional Self-Harm Following Montelukast Use in Patients with Asthma: An Updated Analysis Using ICD-10-CM Coding Retrospective Inferential
03/21/2024
Arterial and Venous Thrombotic Events in Patients with COVID-19 in Inpatient and Ambulatory Settings: A Descriptive Analysis Descriptive
03/12/2024
Racial and Ethnic Differences in the Clinical Characteristics of Patients with Various Stages of COVID-19: A Descriptive Analysis PCORnet Descriptive Analysis
03/11/2024
Utilization and Coding Patterns of Long-Acting Injectable Antipsychotics (LAIA): A Descriptive Analysis Descriptive
03/11/2024
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: An Updated Descriptive Analysis Descriptive
03/08/2024
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: A Descriptive Analysis Descriptive
03/08/2024
Ustekinumab and Comparator Treatment Utilization and Pneumonia Outcomes in Patients with Crohn's Disease or Ulcerative Colitis: An Updated Descriptive Analysis Descriptive
03/07/2024
Capture of Long COVID in TriNetX: A Descriptive Analysis TriNetX Analysis
03/05/2024
Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients Aged 64 or Younger with Atrial Fibrillation: A Descriptive Analysis Descriptive
gastrointestinal bleeding
, intracranial hemorrhage
, major extracranial bleeding
, thromboembolic stroke
View More Outcomes (4)
03/04/2024
Counts and Characteristics of Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis Descriptive
02/27/2024
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients with Diabetes Mellitus: A Descriptive Analysis Descriptive
02/15/2024
Outcome Monitoring Following Dupilumab Use: A Signal Identification Analysis Signal Identification
02/15/2024
Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis Descriptive
01/24/2024
Outcome Monitoring Following Baloxavir Use: A Signal Identification Analysis Signal Identification
01/19/2024
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: A Descriptive Analysis Descriptive
01/16/2024
Medication Use Among Pregnant Patients With COVID-19: A Descriptive Analysis Descriptive
01/11/2024
Utilization of Drug-Device or Biologic-Device Combinations: A Descriptive Analysis Descriptive
12/28/2023
Lipiodol (Ethiodized Oil) and Other Non-Oil Based Iodine Imaging Agent Utilization Patterns: A Descriptive Analysis Descriptive
12/22/2023
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis Descriptive
12/07/2023
Counts and Characteristics of Pegylated Liposomal Doxorubicin and Non-Liposomal Doxorubicin Users: A Descriptive Analysis Descriptive
11/30/2023
Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis PCORnet Descriptive Analysis
11/21/2023
Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis Retrospective Inferential
11/13/2023
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) That Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis Descriptive
alosetron,
alvimopan,
clozapine,
collagenase clostridium histolyticum,
denosumab,
eculizumab,
idelalisib,
isotretinoin,
lenalidomide,
mifepristone,
mycophenolate,
natalizumab,
olanzapine extended release,
panobinostat,
phentermine/topiramate,
pomalidomide,
romiplostim,
teduglutide,
testosterone undecanoate,
vigabatrin
View More Medical Product (20)
10/18/2023
Racial and Ethnic Differences in COVID-19 Treatment and Mortality in TriNetX: A Descriptive Analysis TriNetX Analysis
10/17/2023
Utilization, Dispensing, and Coding Patterns of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis Descriptive
10/11/2023
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential
10/10/2023
Characterization of Use of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis Descriptive
10/10/2023
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis Descriptive
10/02/2023
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis Descriptive
09/15/2023
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Descriptive
09/15/2023
Baloxavir and Oseltamivir Utilization: A Descriptive Analysis Descriptive
08/18/2023
Bevacizumab and Other Cancer Medication Use in Pregnant Patients: A Descriptive Analysis Summary Table
08/04/2023
Incident Utilization of Allopurinol, Hydralazine, and Propylthiouracil: A Descriptive Analysis Summary Table
07/31/2023
Incident Utilization Patterns of Obesity Drugs: A Descriptive Analysis Summary Table
07/26/2023
Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis Descriptive
07/25/2023
Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis Descriptive
07/19/2023
Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis Descriptive
07/19/2023
Characterization of Cannabis-Derived Product Users in TriNetX: Five Descriptive Analyses TriNetX Analysis
07/19/2023
Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis PCORnet Descriptive Analysis
07/18/2023
Prevalence and Characterization of Pharmacogenetic Testing Healthcare Common Procedure Coding System (HCPCS) Procedure Codes in the Mini-Sentinel Distributed Database (MSDD): A Descriptive Analysis Summary Table
07/14/2023
Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis Descriptive
07/10/2023
Alosetron and Eluxadoline Use: A Descriptive Analysis Descriptive
07/06/2023
Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis Descriptive
07/06/2023
Outcome Monitoring Following Erenumab Use: A Signal Identification Analysis Signal Identification
06/22/2023
Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential
06/08/2023
Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis Descriptive
05/24/2023
Ischemic Colitis Following Alosetron Use: A Descriptive Analysis Descriptive
05/24/2023
Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis Descriptive
05/04/2023
Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis Descriptive
05/01/2023
Insulin Coding Practices: A Descriptive Analysis Descriptive
04/27/2023
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis Retrospective Inferential
04/21/2023
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis Retrospective Inferential
04/21/2023
Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis Descriptive
03/22/2023
Utilization of Select Biological Products: A Descriptive Analysis Descriptive
Avastin (bevacizumab),
Epogen (epoetin alfa),
Inflectra (infliximab-dyyb),
Mvasi (bevacizumab-awwb),
Neupogen (filgrastim),
Remicade (infliximab),
Renflexis (infliximab-abda),
Retacrit (epoetin alfa-epbx),
Zarxio (filgrastim-sndz),
Zirabev (bevacizumab-bvzr)
View More Medical Product (10)
03/20/2023
Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis Signal Identification
03/08/2023
Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis Descriptive
all congenital malformations
, congenital cardiac malformations (primary)
, congenital urinary malformations (primary)
View More Outcomes (3)
03/03/2023
Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis Descriptive
all congenital malformations
, congenital cardiac malformations (primary)
, congenital urinary malformations (primary)
View More Outcomes (3)
03/03/2023
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis Descriptive
atrioventricular block
, heart failure
, permanent pacemaker placement
, septal myectomy
, ventricular arrhythmia
View More Outcomes (5)
02/09/2023
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis Descriptive
atrioventricular block
, heart failure
, myocardial infarction
, permanent pacemaker placement
, septal myectomy
, ventricular arrhythmia
View More Outcomes (6)
02/09/2023
Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis TriNetX Analysis
01/12/2023
Identifying Potential Risk Factors for Respiratory Failure: A Covariate Stratified Analysis Retrospective Inferential
01/10/2023
Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis Descriptive
01/10/2023
Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis Descriptive
11/14/2022
Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis Signal Identification
11/10/2022
Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis Signal Identification
11/10/2022
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX TriNetX Analysis
10/31/2022
Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis Retrospective Inferential
any fracture
, hip replacement
, major fracture (primary)
, temporomandibular joint replacement
View More Outcomes (4)
09/16/2022
Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis) Retrospective Inferential
any fracture
, hip replacement
, major fracture (primary)
, temporomandibular joint replacement
View More Outcomes (4)
09/16/2022
Comparative Effectiveness of Azithromycin Relative to Roflumilast in Individuals With Uncontrolled Chronic Obstructive Pulmonary Disease Despite Triple Inhaled Therapy
09/01/2022
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis Descriptive
08/24/2022
Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis Descriptive
08/19/2022
Utilization of Obesity Drugs: A Descriptive Analysis Descriptive
08/05/2022
Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis Descriptive
07/14/2022
Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis Summary Table
07/11/2022
Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis Descriptive
06/30/2022
Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis Retrospective Inferential
06/29/2022
Tacrolimus Use in Patients Following Liver or Kidney Transplants: A Descriptive Analysis Descriptive
06/24/2022
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis Descriptive
06/24/2022
Count and Duration of Follow-up of New-Onset Cancer: An Updated Descriptive Analysis Descriptive
06/23/2022
Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis Retrospective Inferential
06/21/2022
Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis Descriptive
06/14/2022
Outpatient Corticosteroid Use in Patients With COVID-19: An Updated Descriptive Analysis Descriptive
06/02/2022
Outpatient Corticosteroid Use in Patients With COVID-19: A Descriptive Analysis Descriptive
06/01/2022
Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis Descriptive
05/17/2022
Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: A Descriptive Analysis Descriptive
05/16/2022
Death Data Exploration: A Descriptive Analysis Custom Code
04/28/2022
Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 or Older: An Inverse Probability of Treatment Weighting (IPTW) Analysis Retrospective Inferential
gastrointestinal bleeding
, intracranial hemorrhage
, major extracranial bleeding
, thromboembolic stroke
View More Outcomes (4)
04/25/2022
Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis Descriptive
04/21/2022
Duration of Follow Up for New Molecular Entities Approved in 2018: First Descriptive Analysis Descriptive
04/20/2022
Counts and Characteristics of Individuals 25 Years Old or Younger With Drug-Device or Biologic-Device Combination Use: A Descriptive Analysis Descriptive
04/18/2022
Utilization of Brodalumab: A Descriptive Analysis Descriptive
04/05/2022
Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis Descriptive
03/29/2022
Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis Descriptive
03/29/2022
Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis Descriptive
03/29/2022
Epidiolex (Prescription Cannabidiol) Utilization Patterns: A Descriptive Analysis Descriptive
03/28/2022
Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis Descriptive
03/25/2022
Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis Descriptive
03/23/2022
Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis Descriptive
03/11/2022
Drug Utilization Over Time for Six Drug Classes Descriptive
ace inhibitors,
beta blockers,
granulocyte colony-stimulating factor (GC-SF),
intravenous (IV) iron,
statins,
tumor necrosis factor (TNF) alpha inhibitor
View More Medical Product (6)
03/09/2022
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis Descriptive
03/03/2022
Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis Descriptive
03/01/2022
Bleeding Events and Venous Thromboembolism (VTE) following Enoxaparin Use: A Descriptive Analysis Descriptive
02/25/2022
Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis Descriptive
02/24/2022
N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis Descriptive
02/18/2022
Duration of Follow Up for New Molecular Entities Approved in 2019: First Descriptive Analysis Descriptive
01/26/2022
Duration of Follow Up for New Molecular Entities Approved in 2017: Second Descriptive Analysis Descriptive
01/21/2022
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis Retrospective Inferential
12/15/2021
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis) Retrospective Inferential
12/15/2021
Racial Differences in COVID-19 Outcomes (2020-2021) Retrospective Inferential
12/08/2021
Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis Descriptive
alemtuzumab,
cladribine,
dalfampridine,
dimethyl fumarate,
diroximel fumarate,
fingolimod,
glatiramer acetate,
interferon beta-1A,
interferon beta-1B,
mitoxantrone,
natalizumab,
ocrelizumab,
peginterferon beta-1a,
siponimod,
teriflunomide
View More Medical Product (15)
10/20/2021
Oral Metoclopramide Use: A Descriptive Analysis Descriptive
09/30/2021
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) That Employ Elements to Assure Safe Use (ETASU) Summary Table
08/23/2021
Duration of Follow Up for New Molecular Entities Approved in 2017: First Descriptive Analysis Descriptive
08/13/2021
Brand and Generic Tacrolimus Use following Kidney, Heart, and Liver Transplants: A Descriptive Analysis Descriptive
08/11/2021
Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis Descriptive
05/18/2021
Utilization of Sacubitril/Valsartan: A Descriptive Analysis Descriptive
04/19/2021
Duration of Follow Up for New Molecular Entities Approved in 2011 Descriptive
04/16/2021
Patterns in Insulin Product Use and Billing Codes: A Descriptive Analysis Descriptive
04/16/2021
Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007 Descriptive
04/16/2021
Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009 Descriptive
04/16/2021
Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013 Descriptive
04/16/2021
Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015 Descriptive
04/16/2021
Duration of Follow Up for New Molecular Entities Approved in 2016 Descriptive
04/16/2021
Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: First Descriptive Analysis Descriptive
03/30/2021